JP2005526790A - アポモルフィンおよび類縁体の配糖体およびオルトエステル配糖体誘導体、ならびにそれらの使用方法 - Google Patents

アポモルフィンおよび類縁体の配糖体およびオルトエステル配糖体誘導体、ならびにそれらの使用方法 Download PDF

Info

Publication number
JP2005526790A
JP2005526790A JP2003577900A JP2003577900A JP2005526790A JP 2005526790 A JP2005526790 A JP 2005526790A JP 2003577900 A JP2003577900 A JP 2003577900A JP 2003577900 A JP2003577900 A JP 2003577900A JP 2005526790 A JP2005526790 A JP 2005526790A
Authority
JP
Japan
Prior art keywords
glycoside
apomorphine
derivative
derivative according
orthoester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003577900A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526790A5 (enExample
Inventor
ミシェル ホリック
ハラシャ ラマナサン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2005526790A publication Critical patent/JP2005526790A/ja
Publication of JP2005526790A5 publication Critical patent/JP2005526790A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2003577900A 2002-03-19 2003-03-19 アポモルフィンおよび類縁体の配糖体およびオルトエステル配糖体誘導体、ならびにそれらの使用方法 Withdrawn JP2005526790A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36545402P 2002-03-19 2002-03-19
PCT/US2003/008448 WO2003080074A1 (en) 2002-03-19 2003-03-19 Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof

Publications (2)

Publication Number Publication Date
JP2005526790A true JP2005526790A (ja) 2005-09-08
JP2005526790A5 JP2005526790A5 (enExample) 2006-03-09

Family

ID=28454658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003577900A Withdrawn JP2005526790A (ja) 2002-03-19 2003-03-19 アポモルフィンおよび類縁体の配糖体およびオルトエステル配糖体誘導体、ならびにそれらの使用方法

Country Status (9)

Country Link
US (1) US20060004190A1 (enExample)
EP (1) EP1496915A1 (enExample)
JP (1) JP2005526790A (enExample)
KR (1) KR20050008658A (enExample)
CN (1) CN1720054A (enExample)
AU (1) AU2003223304A1 (enExample)
BR (1) BR0308567A (enExample)
CA (1) CA2479372A1 (enExample)
WO (1) WO2003080074A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018500350A (ja) * 2014-12-23 2018-01-11 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ アポモルヒネの結晶形態およびその使用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
FR2939436B1 (fr) * 2008-12-10 2010-12-17 Sanofi Aventis Synthese de morphine-6-glucuronide ou de l'un de ses derives
DK2952191T3 (en) 2009-06-12 2018-12-10 Sunovion Pharmaceuticals Inc Sublingual apomorphine
CA3115378A1 (en) 2010-12-16 2012-06-21 Sunovion Pharmaceuticals Inc. Sublingual films comprising apomorphine and an organic base
NZ703341A (en) 2012-06-05 2016-11-25 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
EP3524247A1 (en) 2013-11-11 2019-08-14 Impax Laboratories, Inc. Rapidly disintegrating formulations and methods of use
KR102712887B1 (ko) 2017-11-24 2024-10-02 하. 룬드벡 아크티에셀스카브 파킨슨병의 치료에 사용하기 위한 새로운 카테콜아민 전구약물
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
JP7562562B2 (ja) 2019-05-21 2024-10-07 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
CN113677675B (zh) 2019-05-21 2024-07-26 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
US12398106B2 (en) 2019-05-21 2025-08-26 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson's disease
EP3972970A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
CN114773409B (zh) * 2022-04-27 2023-12-15 江西艾立斯特生物科技有限公司 一种2,3,4,6-四-o-乙酰基-吡喃葡萄糖的制备方法
WO2023242355A1 (en) 2022-06-15 2023-12-21 Ever Neuro Pharma Gmbh Apomorphine prodrugs and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4785014A (en) * 1985-06-07 1988-11-15 Yale University Use of clonidine in memory enhancement
PT689438E (pt) * 1993-03-26 2003-10-31 Franciscus Wilhelmus He Merkus Composicoes farmaceuticas para administracao intranasal de apomorfina
ATE189121T1 (de) * 1994-04-22 2000-02-15 Pentech Pharmaceuticals Inc Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US5744476A (en) * 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US6011043A (en) * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6001845A (en) * 1998-06-19 1999-12-14 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
AU4696499A (en) * 1998-06-19 2000-01-05 Genetronics, Inc. Electrically assisted transdermal method and apparatus for the treatment of erectile dysfunction
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
SK15772002A3 (sk) * 2000-04-07 2003-09-11 Tap Pharmaceutical Products Inc. Deriváty apomorfínu, ich použitie a farmaceutická kompozícia s ich obsahom

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018500350A (ja) * 2014-12-23 2018-01-11 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ アポモルヒネの結晶形態およびその使用

Also Published As

Publication number Publication date
KR20050008658A (ko) 2005-01-21
CN1720054A (zh) 2006-01-11
CA2479372A1 (en) 2003-10-02
US20060004190A1 (en) 2006-01-05
BR0308567A (pt) 2007-01-09
WO2003080074A1 (en) 2003-10-02
AU2003223304A1 (en) 2003-10-08
EP1496915A1 (en) 2005-01-19

Similar Documents

Publication Publication Date Title
JP2005526790A (ja) アポモルフィンおよび類縁体の配糖体およびオルトエステル配糖体誘導体、ならびにそれらの使用方法
US6872713B1 (en) Antiprotozoal saponins
CN103781472A (zh) 丙泊酚苷衍生物的合成和使用
HK60297A (en) Androstane 17-carboxylic-acid esters, their preparation and medicaments containing them
JP2579654B2 (ja) アントラサイクリン誘導体
Ma et al. Synthesis of steroidal glycosides bearing the disaccharide moiety of OSW-1 and their antitumor activities
WO2003094842A2 (en) Conjugates comprising central nervous system active drug
US7217696B2 (en) Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
CA2528223C (en) Colchicoside analogues
KR100547253B1 (ko) 암 예방 및 치료에 유효한 진세노사이드 유도체
US6548485B2 (en) Stable antitumor drug
JP2015517535A (ja) 改善された合成
HK1084020A (en) Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
US20050107310A1 (en) Carboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
EP0873347A2 (fr) Nouveaux derives amines de 2", 3" didesoxyglycosides d'epipodophyllotoxine, leur procede de preparation, leur utilisation comme medicament et leur utilisation destinee aux traitements anticancereux
EP3636642B1 (en) Indoleacetic acid derivatives for use in the treatment of cough
JP2005511550A (ja) エトポシドおよび類似体の誘導体、ならびにそれを含有する医薬組成物
WO2001027129A1 (en) Glycosides and orthoester glycosides of raloxifene and analogues and the use thereof
KR100461302B1 (ko) 신규 슈도에리쓰로마이신 유도체
KR20050117501A (ko) 진세노사이드 유도체의 제조방법
US4169890A (en) Pharmaceutical composition containing 5"-amino-3',5"-dideoxy-ribostamycin and intermediate compounds
EP2376511B1 (fr) Derives bicycliques de morphine-6-glucuronide, leur preparation et leur application en therapeutique
US9365502B2 (en) Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors
Basu et al. Parasuraman Jaisankar, Bikash Pal, Ranjan K. Manna, Prasun K. Pradhan, S. Medda b
NL8101064A (nl) Nogalamycinederivaten en werkwijze voor het bereiden daarvan alsmede daaruit bereide c.q. vervaardigde farmaceutische preparaten.

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20051019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060119

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070511